American trade negotiators tried to break local biotech CSL’s control of the Australian blood plasma market, in a move that chairman Brian McNamee says helped spur the company to transform into a global powerhouse.
Newly released Howard government cabinet documents from 20 years ago reveal the pressure the United States placed on Australia to open up CSL’s exclusive contract with the federal government and Red Cross for plasma fractionation services.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.